Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 26:8:F1000 Faculty Rev-970.
doi: 10.12688/f1000research.17401.1. eCollection 2019.

Recent advances in HIV-associated Kaposi sarcoma

Alessia Dalla Pria  1   2 , David J Pinato  1   2 , Margherita Bracchi  2 , Mark Bower  1   2
Affiliations
Review

Recent advances in HIV-associated Kaposi sarcoma

Alessia Dalla Pria et al. F1000Res. .

Abstract

Kaposi sarcoma (KS) is a mesenchymal tumour caused by KS-associated herpesvirus and is an AIDS-defining illness. Despite a decline in incidence since the introduction of combination anti-retroviral therapy, KS remains the most common cancer in people living with HIV in sub-Saharan Africa, where it causes significant morbidity and mortality. This review reflects on recent epidemiological data as well as current management, unmet needs and future perspectives in the treatment of HIV-associated KS with particular emphasis on the potential role of immune checkpoint inhibitors.

Keywords: HIV; KS; cART.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.Competing interests: Robert Yarchoan is a co-inventor on US Patent 10,001,483 entitled "Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers". The patent application for this was filed in part based on the results of NCI protocol 12-C-0047, entitled "A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals with or without HIV". It is his understanding that foreign patents have also been filed for this invention. This invention was made as a full-time employee of the US government under 45 Code of Federal Regulations Part 7. His spouse, who is also a US Government employee, has a patent on KSHV viral IL-6. All rights, title, and interest to these patents have been or should by law be assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee-inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). Robert Yarchoan's research is funded in part by Cooperative Research and Development Agreements (CRADAs) between Celgene Corporation and the National Cancer Institute. As part of this agreement, Celgene has provided drugs for clinical trials. Bevacizumab for his trial of bevacizumab alone and with liposomal doxorubicin was provided to the NCI under a CRADA with Genetech, and drugs for his trial of pembrolizumab is provided to the NCI by a CRADA with Merck & Co.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cook-Mozaffari P, Newton R, Beral V, et al. : The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998;78(11):1521–8. 10.1038/bjc.1998.717 - DOI - PMC - PubMed
    1. Stefan DC: Patterns of distribution of childhood cancer in Africa. J Trop Pediatr. 2015;61(3):165–73. 10.1093/tropej/fmv005 - DOI - PubMed

    2. F1000 Recommendation

    1. Ziegler JL, Katongole-Mbidde E: Kaposi's sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer. 1996;65(2):200–3. 10.1002/(SICI)1097-0215(19960117)65:2<200::AID-IJC12>3.0.CO;2-H - DOI - PubMed
    1. WHO: Globocan 2018 - Home. Globocan 2018.2018. NO: 11.
    1. Gallafent JH, Buskin SE, de Turk PB, et al. : Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol. 2005;23(6):1253–60. 10.1200/JCO.2005.04.156 - DOI - PubMed